Enlivex Ltd. (ENLV)
1.11
+0.01
(+0.91%)
USD |
NASDAQ |
Sep 08, 16:00
1.13
+0.02
(+1.80%)
Pre-Market: 09:15
Enlivex Enterprise Value : 12.34M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 12.34M |
| September 04, 2026 | 12.18M |
| September 03, 2026 | 13.13M |
| September 02, 2026 | 14.55M |
| September 01, 2026 | 15.03M |
| August 31, 2026 | 15.03M |
| August 28, 2026 | 16.14M |
| August 27, 2026 | 18.12M |
| August 26, 2026 | 18.75M |
| August 25, 2026 | 18.83M |
| August 24, 2026 | 18.67M |
| August 21, 2026 | 18.04M |
| August 20, 2026 | 18.51M |
| August 19, 2026 | 22.15M |
| August 18, 2026 | 18.83M |
| August 17, 2026 | 19.78M |
| August 14, 2026 | 19.78M |
| August 13, 2026 | 21.52M |
| August 12, 2026 | 23.89M |
| August 11, 2026 | 25.16M |
| August 10, 2026 | 26.58M |
| August 07, 2026 | 27.69M |
| August 06, 2026 | 26.11M |
| August 05, 2026 | 29.27M |
| August 04, 2026 | 28.16M |
| Date | Value |
|---|---|
| August 03, 2026 | 29.11M |
| July 31, 2026 | 27.85M |
| July 30, 2026 | 25.63M |
| July 29, 2026 | 30.38M |
| July 28, 2026 | 30.22M |
| July 27, 2026 | 62.19M |
| July 24, 2026 | 61.24M |
| July 23, 2026 | 63.77M |
| July 22, 2026 | 67.33M |
| July 21, 2026 | 69.63M |
| July 20, 2026 | 68.20M |
| July 17, 2026 | 68.84M |
| July 16, 2026 | 69.94M |
| July 15, 2026 | 87.19M |
| July 14, 2026 | 90.52M |
| July 13, 2026 | 100.33M |
| July 10, 2026 | 103.34M |
| July 09, 2026 | 111.88M |
| July 08, 2026 | 108.83M |
| July 07, 2026 | 112.04M |
| July 06, 2026 | 116.34M |
| July 02, 2026 | 120.01M |
| July 01, 2026 | 123.34M |
| June 30, 2026 | 125.31M |
| June 29, 2026 | 132.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Polyrizon Ltd. | -- |
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 12.28M |
| Summit Therapeutics, Inc. | 13.03B |
| PeptiDream Inc. | 851.28M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.243B |
| Total Expenses (Quarterly) | -1.243B |
| EPS Diluted (Quarterly) | 386.85 |
| Earnings Yield | 34.43K% |
| Normalized Earnings Yield | 2388.04 |